Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Brief Summary

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Website: https://clinicaltrials.gov/study/NCT05079282

Sponsors and Collaborators: Ono Pharmaceutical Co. Ltd

Contacts and Locations

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05079282

Recruiting

Participating Locations:

Chao Family Comprehensive Cancer Center
Orange, CA, United States
Contact
Ono Pharma USA, Inc.
clinical_trial@ono-pharma.com
Recruiting
University of Alabama at Birmingham
Birmingham, AL, United States
Contact
Ono Pharma USA, Inc.
clinical_trial@ono-pharma.com
Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, NY, United States
Contact
Ono Pharma USA, Inc.
clinical_trial@ono-pharma.com
Recruiting
Columbia University Irving Medical Center
New York, NY, United States
Contact
Ono Pharma USA, Inc.
clinical_trial@ono-pharma.com
Recruiting
Memorial Sloan Kettering Cancer Center
New York, NY, United States
Contact
Ono Pharma USA, Inc.
clinical_trial@ono-pharma.com
Recruiting
Oregon Health & Science University
Portland, OR, United States
Contact
Ono Pharma USA, Inc.
clinical_trial@ono-pharma.com
Recruiting
Dallas, TX, United States
Contact
Ono Pharma USA, Inc.
clinical_trial@ono-pharma.com
Recruiting
UT MD Anderson Cancer Center
Houston, TX, United States
Contact
Ono Pharma USA, Inc.
clinical_trial@ono-pharma.com
Recruiting